Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001781PROCESS FOR THE PREPARATION OF N-HYDROXYPYRIDONE COMPOUNDS
WO 26.01.2023
Int.Class C07D 213/89
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
89with hetero atoms directly attached to the ring nitrogen atom
Appl.No PCT/EP2022/070105 Applicant CLARIANT INTERNATIONAL LTD Inventor FISCH, Lothar
The invention relates to a process for the preparation of N- hydroxypyridone compounds (I) from pyrone compounds. The N- hydroxypyridone compounds (I) can be used as anti-dandruff agents or as preservatives.
2.WO/2023/003002ANNULATED PYRIDAZINE COMPOUND
WO 26.01.2023
Int.Class C07D 237/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
26condensed with carbocyclic rings or ring systems
30Phthalazines
32with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Appl.No PCT/JP2022/028138 Applicant ASTELLAS PHARMA INC. Inventor INAGAKI, Yusuke
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the present invention conducted extensive studies to find a compound that has an inhibiting action on NLRP3 inflammasome activation, and found that an annulated pyridazine compound has an inhibiting action on NLRP3 inflammasome activation, leading to the achievement of the present invention. The annulated pyridazine compound according to the present invention is expected to serve as a drug for preventing and/or treating inflammatory diseases and/or a neurodegenerative diseases.
3.WO/2023/001247PYRIDAZINONE COMPOUND
WO 26.01.2023
Int.Class C07D 403/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
Appl.No PCT/CN2022/107127 Applicant MEDSHINE DISCOVERY INC. Inventor FU, Xiangyu
A series of pyridazinone compounds and pharmaceutically acceptable salts thereof, and an application thereof in the preparation of a drug for treating a related disease. Specifically disclosed are a compound of formula (IV) and a pharmaceutically acceptable salt thereof.
4.WO/2023/004382SUBSTITUTED HETERO-BICYCLOCOMPOUNDS AS SUBTYPE SELECTIVE NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
WO 26.01.2023
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/US2022/073998 Applicant THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS Inventor RILEY, Andrew
In one aspect, the disclosure relates to a scaffold for a class of small molecules that selectively inhibit the α3β4 nicotinic acetylcholine receptor (nAChR) subtype, as well as molecules constructed using the scaffold and syntheses thereof. In some aspects, the scaffold can be used as a basis for synthesizing additional molecules capable of selectively inhibiting other nAChR subtypes. In a further aspect, the disclosed small molecules can be used as molecular probes to investigate the function of different nAChR subtypes and as potential treatments for addiction and other diseases.
5.WO/2023/004427TREATMENT OF SEVERE AND UNCOMPLICATED MALARIA
WO 26.01.2023
Int.Class A61P 33/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
33Antiparasitic agents
02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
06Antimalarials
Appl.No PCT/US2022/074071 Applicant LOW, Philip Inventor LOW, Philip
Methods of treating severe and uncomplicated malaria comprising administering an isoform of artemisinin, a hydrophobic amine, and a spleen tyrosine kinase (Syk) inhibitor. Further provided is a unitary, oral dosage form comprising an isoform of artemisinin, a hydrophobic amine, and a Syk inhibitor; and a kit comprising multiple unitary, oral dosage forms and instructions for administration.
6.WO/2023/000708POLYSUBSTITUTED PURINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO 26.01.2023
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2022/083786 Applicant CHINA PHARMACEUTICAL UNIVERSITY Inventor YANG, Peng
Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory effect on RNA adenosine deaminase 1 (ADAR1) and can be used for preventing and/or treating cancer or tumor-related diseases caused by abnormal activity of such enzymes, especially prostate cancer, leukemia, breast cancer, multiple myeloma, lung cancer, stomach cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases.
7.WO/2023/001323CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF
WO 26.01.2023
Int.Class C07C 233/62
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
233Carboxylic acid amides
57having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
62having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
Appl.No PCT/CZ2022/050065 Applicant USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V.V.I. Inventor CIGLER, Petr
The present invention relates to a lipidoid of general formula I, wherein X is selected from -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C≡C-, -CH=CH-, a five-membered heterocycle containing at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, and -CH=N-NH-; Y is alkylene C2-C10 chain; R1 is selected from alkyl C1-C46, alkenyl C2-C46, alkynyl C2-C46; Z is selected from H, -OH, -CH3, -CH2OH, -NH2, -C(=O)NH2, -CONH(CH2)2OH, -CON[(CH2)2OH]2, -CONHCH(CH2OH)2, -CONHCH2CH(-OH)CH2OH, -CONH(CH2)2C(=O)NH2, -CON[CH2C(=O)NH2]2, -CONH(CH2)2NHC(=O)NH2, -CONH(CH2)3-N+(CH3)2-(CH2)2-SO3–, -CONH(CH2)3-N+(CH3)2-(CH2)2-COO–, -COO(CH2)2-O-P(=O)(O–)-O(CH2)2-N+(CH3)3, -N+(CH3)2-(CH2)3-SO3–, -N+(CH3)2-(CH2)2-COO-, formula (II), and formula (III), wherein R2 is independently selected from hydrogen and -CH3; E is independently selected from O and S atoms; n is an integer within the range of from 1 to 5; and T is selected from -X-Y-N(R1)2, -C(=O)O(C1-C3 alkyl), -C(=O)OCH2CH2OH, formula (IV), formula (V), formula (VI), -C(=O)OH, -CONH(CH2)2OH, -CON[(CH2)2OH]2, -CONHCH(CH2OH)2, CONH(CH2)2C(=O)NH2, -CON[CH2C(=O)NH2]2, -CONHCH[C(=O)NH2]2, -CONH(CH2)2NHC(=O)NH2, -C(=O)NH2, -CONH(CH2)3-N+(CH3)2-(CH2)2-SO3–, -CONH(CH2)3-N+(CH3)2-(CH2)2-COO–, -NH2, -NHC(=O)CH3, -COO(CH2)2-O-P(=O)(O–)-O(CH2)2-N+(CH3)3, -OH, -O(C1-C3 alkyl), -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2, -N+(CH3)2-(CH2)3-SO3–, -N+(CH3)2-(CH2)2-COO–, wherein R2, E and n are as defined above; and/or if Z is -OH or -CH2OH, and T is -C(=O)OH, then Z together with T and three carbon atoms between them may form a cyclic lactone containing 4 to 5 carbon atoms; and pharmaceutically acceptable salts, addition salts and solvates thereof. This lipidoid is useful as a transfection agent. The invention further describes transfection reagents, transfection particles containing this lipidoid, and their use.
8.WO/2023/001338COMPOUND, RUBBER BLEND CONTAINING THE COMPOUND, VEHICLE TIRE COMPRISING THE RUBBER BLEND IN AT LEAST ONE COMPONENT, PROCESS FOR PRODUCING THE COMPOUND, AND USE OF THE COMPOUND AS AN AGEING PROTECTANT AND/OR ANTIOZONANT AND/OR DYE
WO 26.01.2023
Int.Class C07D 219/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
219Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
04with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
08Nitrogen atoms
Appl.No PCT/DE2022/200128 Applicant CONTINENTAL REIFEN DEUTSCHLAND GMBH Inventor JACOB, Andreas
The invention relates to a compound, a rubber blend containing said compound, a vehicle tire comprising the rubber blend in at least one component, a process for producing the compound and the use of the compound as ageing protectant and/or antiozonant and/or dye. The compound according to the invention has the formula (I) wherein R1 is selected from the group consisting of benzyl groups, 1-phenylalkyl groups with a total of 7 to 18 carbon atoms and linear, branched and cyclic aliphatic C3 to C12 groups.
9.WO/2023/002928FILM-FORMING MATERIAL FOR SEMICONDUCTOR, MEMBER-FORMING MATERIAL FOR SEMICONDUCTOR, PROCESS MEMBER-FORMING MATERIAL FOR SEMICONDUCTOR, UNDERLAYER FILM-FORMING MATERIAL, UNDERLAYER FILM, AND SEMICONDUCTOR DEVICE
WO 26.01.2023
Int.Class G03F 7/11
GPHYSICS
03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
FPHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
7Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
004Photosensitive materials
09characterised by structural details, e.g. supports, auxiliary layers
11having cover layers or intermediate layers, e.g. subbing layers
Appl.No PCT/JP2022/027788 Applicant ADEKA CORPORATION Inventor SAITO, Hiromasa
The purpose of the present invention is to provide a film-forming material for a semiconductor which yields a film having excellent heat resistance and solvent resistance. The present invention is a film-forming material for a semiconductor including: a compound represented by general formula (I) and having one or more reactive groups in the molecule thereof, or a polymer in which the compound represented by general formula (I) and having one or more reactive groups in the molecule thereof serves as a monomer; and a solvent. In the formula, A represents a hydrocarbon ring having six carbon atoms, X1 and X2 each represent a reactive group or an aryl group or the like having 6-30 carbon atoms and in which a group having a reactive group may be substituted, R1, R2, R3, R4, R6, R7, R8, and R9 each represent a hydrogen atom, a reactive group, or a hydrocarbon group or the like having 1-20 carbon atoms and in which a reactive group may be substituted, and R5 and R10 each represent a hydrogen atom or a hydrocarbon group or the like having 1-20 carbon atoms and in which a reactive group may be substituted.
10.WO/2023/003468NOVEL INHIBITORS OF HISTONE DEACETYLASE (HDAC), AND METHODS, COMPOSITIONS AND USES RELATED THERETO.
WO 26.01.2023
Int.Class C07D 213/75
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72Nitrogen atoms
75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Appl.No PCT/NL2022/050429 Applicant RIJKSUNIVERSITEIT GRONINGEN Inventor ZWINDERMAN, Reint Harm
The invention relates to the field of medicinal chemistry and pharmacology, specifically to novel inhibitors of histone deacetylase (HDAC), and to compositions, methods of making, and using them, for instance in the treatment of chronic obstructive pulmonary disease (COPD). Provided is a compound of the formula A or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein A is H or an in vivo hydrolysable group, and L is a linker group.